Tirzepatide Clinical Trials: Registered Studies and Status
As of November 2, 2026, ClinicalTrials.gov lists 270 registered studies matching Tirzepatide or its known aliases as an intervention.
Summary
- Registered studies
- 270
- Most advanced phase
- Phase 4
- Recruiting or not yet recruiting
- 135
- Most recent start
- 2027-12-12
- Most frequent lead sponsor
- Eli Lilly and Company (81)
- Most common status
- Completed
Source: ClinicalTrials.gov, retrieved . Registry searches by name may miss studies that use other identifiers.
Registered studies
| NCT ID | Title | Phase | Status | Enrollment | Start | Lead sponsor |
|---|---|---|---|---|---|---|
| NCT07728318 | Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients | Not applicable | Not yet recruiting | 52 | 2027-12-12 | Akhtar Saeed Medical and Dental College |
| NCT07265752 | Tirzepatide for the Treatment of Cannabis Use Disorder | Phase 2 | Not yet recruiting | 6 | 2027-03-01 | Brigham and Women's Hospital |
| NCT07847515 | Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients | N/A | Not yet recruiting | 80 | 2027-02-01 | Nanjing First Hospital, Nanjing Medical University |
| NCT07622992 | Preoperative Optimization With Tirzepatide, Ketogenic Diet, or Standard Care Before One Anastomosis Gastric Bypass Surgery | N/A | Not yet recruiting | 96 | 2027-01-01 | Mario Musella MD |
| NCT07078838 | Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer | Phase 2 | Not yet recruiting | 40 | 2027-01 | UNC Lineberger Comprehensive Cancer Center |
| NCT07829198 | Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial | Phase 3 | Not yet recruiting | 70 | 2027-01 | Universidade do Porto |
| NCT07889648 | A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications | Phase 3 | Not yet recruiting | 948 | 2026-12-01 | Hoffmann-La Roche |
| NCT06180616 | Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity | Phase 2 | Not yet recruiting | 40 | 2026-12 | Royal North Shore Hospital |
| NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Phase 3 | Not yet recruiting | 2115 | 2026-12 | Eli Lilly and Company |
| NCT07468552 | Trial of Tirzepatide for the Treatment of Cannabis Use Disorder | Phase 2 | Not yet recruiting | 100 | 2026-11-15 | National Institute on Drug Abuse (NIDA) |
| NCT07855900 | SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Phase 3 | Not yet recruiting | 350 | 2026-11-07 | Boehringer Ingelheim |
| NCT07796477 | A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin | Phase 2 | Not yet recruiting | 240 | 2026-11-06 | CSPC Ouyi Pharmaceutical Co., Ltd. |
| NCT07349641 | A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer | Phase 2 | Not yet recruiting | 55 | 2026-11-01 | National Cancer Institute (NCI) |
| NCT07812636 | Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer | Early phase 1 | Not yet recruiting | 15 | 2026-11-01 | Milton S. Hershey Medical Center |
| NCT07099742 | Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) | N/A | Not yet recruiting | 364 | 2026-11 | Dr. Md. Alimur Reza |
| NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Not yet recruiting | 1000 | 2026-11 | Eli Lilly and Company |
| NCT07900074 | Mechanisms of Weight Loss: Tirzepatide vs Semaglutide | Phase 4 | Recruiting | 80 | 2026-10-31 | McMaster University |
| NCT07893457 | Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity | Phase 4 | Not yet recruiting | 30 | 2026-10-26 | Mayo Clinic |
| NCT07825857 | Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | Phase 2 | Recruiting | 228 | 2026-10-23 | University of Texas Southwestern Medical Center |
| NCT07782359 | Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib | Phase 1 | Recruiting | 30 | 2026-10-22 | University of Chicago |
| NCT07889453 | Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide | N/A | Active not recruiting | 650 | 2026-10-15 | LMC Diabetes & Endocrinology Ltd. |
| NCT07874828 | PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study | Phase 2 | Recruiting | 30 | 2026-10-14 | M.D. Anderson Cancer Center |
| NCT07868354 | A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication | Phase 1 | Recruiting | 60 | 2026-10-08 | Novo Nordisk A/S |
| NCT07777575 | Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Phase 4 | Recruiting | 150 | 2026-10-07 | Technical University of Munich |
| NCT07809568 | Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes | N/A | Not yet recruiting | 330 | 2026-10-01 | Universiti Sains Malaysia |
| NCT07846865 | Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial | Phase 2 / Phase 3 | Not yet recruiting | 256 | 2026-10-01 | Woolcock Institute of Medical Research |
| NCT07387796 | Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation | Not applicable | Recruiting | 40 | 2026-10 | The University of Texas at Dallas |
| NCT07906041 | Tirzepatide and Organ-specific Biological Aging | Phase 2 | Enrolling by invitation | 22 | 2026-10 | Atria Research and Global Health Institute (ARGHI) |
| NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Phase 3 | Recruiting | 660 | 2026-09-30 | Pfizer |
| NCT07817875 | Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS) | Phase 3 | Recruiting | 150 | 2026-09-25 | Eli Lilly and Company |
| NCT07734792 | Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial | Phase 2 / Phase 3 | Not yet recruiting | 726 | 2026-09-20 | yifang zhu |
| NCT07734870 | Tirzepatide for Treatment of CCCA | Phase 2 | Recruiting | 20 | 2026-09-15 | Johns Hopkins University |
| NCT07803744 | A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | Phase 1 | Recruiting | 18 | 2026-09-11 | Eli Lilly and Company |
| NCT07715929 | Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients | Phase 4 | Not yet recruiting | 710 | 2026-09-01 | Yunlong Wang |
| NCT07756359 | Tirzepatide for Ileal Pouch-anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F-NS-X008) | Phase 4 | Not yet recruiting | 20 | 2026-09 | University of North Carolina, Chapel Hill |
| NCT07811895 | Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer | Not applicable | Not yet recruiting | 1510 | 2026-09 | RenJi Hospital |
| NCT07747805 | GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD | Phase 2 | Not yet recruiting | 30 | 2026-08-28 | The Cleveland Clinic |
| NCT07842640 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight | Phase 1 | Recruiting | 84 | 2026-08-27 | Ascletis Pharma (China) Co., Limited |
| NCT07191873 | Tirzepatide in Idiopathic Intracranial Hypertension Trial | Phase 4 | Recruiting | 60 | 2026-08-25 | Duke University |
| NCT07693608 | An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | Phase 2 | Active not recruiting | 45 | 2026-08-19 | University of Texas Southwestern Medical Center |
| NCT06732245 | Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese | Phase 2 | Not yet recruiting | 224 | 2026-08-15 | Biomed Industries, Inc. |
| NCT07760532 | Comparing Facial Aging Between Identical Twins With 3D Imaging | N/A | Not yet recruiting | 200 | 2026-08-08 | Ponsky Facial Aesthetics And Plastic Surgery, Llc |
| NCT07554638 | Incretin Therapies in Obesity-related HFpEF | Phase 4 | Recruiting | 50 | 2026-08-07 | Columbia University |
| NCT07619989 | Transcutaneous Auricular Vagus Nerve Stimulation for Poor Weight-Loss Response to Incretin Receptor Agonists | Not applicable | Recruiting | 24 | 2026-08-01 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
| NCT07630454 | Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF | Phase 4 | Not yet recruiting | 602 | 2026-08-01 | Yunlong Wang |
| NCT07671248 | Tirzepatide in the Treatment of Cannabis Use Disorder | Phase 3 | Not yet recruiting | 15 | 2026-08-01 | McMaster University |
| NCT07676331 | Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial | Phase 2 | Not yet recruiting | 168 | 2026-08-01 | Universitaire Ziekenhuizen KU Leuven |
| NCT07298915 | The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED) | Phase 3 | Not yet recruiting | 24 | 2026-08 | University of Virginia |
| NCT07671391 | A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body in Obese Participants | Phase 2 | Not yet recruiting | 60 | 2026-08 | Shanghai Zhongshan Hospital |
| NCT07573163 | Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion | Phase 2 | Recruiting | 34 | 2026-07-27 | Alaa Sada |
| NCT07588438 | Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay. | Phase 4 | Recruiting | 160 | 2026-07-27 | Las Rías Medical Center |
| NCT07697391 | AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes | Phase 4 | Not yet recruiting | 285 | 2026-07-20 | The First Affiliated Hospital of Anhui Medical University |
| NCT07738276 | Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | Phase 3 | Not yet recruiting | 60 | 2026-07-18 | Shahid Beheshti University of Medical Sciences |
| NCT06820281 | Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes | Phase 2 | Recruiting | 44 | 2026-07-07 | Victor Chang Cardiac Research Institute |
| NCT07635953 | New Triple Combination Therapy in Newly Diagnosed Type 2 Diabetes | Phase 3 | Not yet recruiting | 296 | 2026-07-01 | Sun Yat-sen University |
| NCT07706088 | Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy | Phase 4 | Not yet recruiting | 40 | 2026-07 | Post Graduate Institute of Medical Education and Research, Chandigarh |
| NCT07866183 | Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study | Not applicable | Recruiting | 120 | 2026-06-29 | National Medical Research Center for Therapy and Preventive Medicine |
| NCT07707778 | Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV | Phase 4 | Enrolling by invitation | 60 | 2026-06-25 | National Taiwan University Clinical Trial Center |
| NCT07382024 | Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation | Not applicable | Not yet recruiting | 200 | 2026-06-16 | National Taiwan University Hospital |
| NCT07046819 | Tirzepatide in MetALD | Phase 2 | Recruiting | 120 | 2026-06-11 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT07257484 | Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors | Phase 4 | Recruiting | 30 | 2026-06-08 | Weill Medical College of Cornell University |
| NCT07602699 | Multi-Site Trial of Tirzepatide for Smoking Cessation | Phase 2 | Recruiting | 300 | 2026-06-05 | University of Southern California |
| NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer | Phase 2 | Not yet recruiting | 30 | 2026-06-01 | Rutgers, The State University of New Jersey |
| NCT07858864 | GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | N/A | Recruiting | 42 | 2026-05-30 | Istanbul Saglik Bilimleri University |
| NCT07650149 | Genetic, Microbiological and Behavioral Factors in Obesity | N/A | Recruiting | 200 | 2026-05-23 | Jan Kochanowski University |
| NCT07527910 | A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD | Phase 2 | Recruiting | 204 | 2026-05-22 | Regeneron Pharmaceuticals |
| NCT07559500 | Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD) | Phase 1 | Recruiting | 176 | 2026-05-20 | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
| NCT07284511 | A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar | Phase 2 / Phase 3 | Recruiting | 105 | 2026-05-19 | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| NCT07574723 | Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity | Not applicable | Recruiting | 68 | 2026-05-15 | Dasman Diabetes Institute |
| NCT07179120 | Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Phase 2 | Not yet recruiting | 180 | 2026-05-01 | First Affiliated Hospital of Wenzhou Medical University |
| NCT07633639 | GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | Not applicable | Recruiting | 200 | 2026-05-01 | China-Japan Friendship Hospital |
| NCT07567378 | CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry | N/A | Not yet recruiting | 30 | 2026-05 | JULIO GRANADOS MONTIEL |
| NCT07555730 | AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN) | Phase 4 | Not yet recruiting | 400 | 2026-04-30 | Huazhong University of Science and Technology |
| NCT07588984 | GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study | N/A | Not yet recruiting | 2310 | 2026-04-30 | Noom Inc. |
| NCT07065552 | Tirzepatide in Obesity-Driven Endometrial Cancer | Early phase 1 | Recruiting | 20 | 2026-04-27 | UNC Lineberger Comprehensive Cancer Center |
| NCT07228741 | Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity | Phase 2 | Recruiting | 20 | 2026-04-23 | St. Jude Children's Research Hospital |
| NCT07653412 | Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | N/A | Recruiting | 220 | 2026-04-22 | National and Kapodistrian University of Athens |
| NCT07218445 | The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity | Phase 4 | Recruiting | 40 | 2026-04-08 | Mayo Clinic |
| NCT06811324 | Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults | Phase 2 | Recruiting | 20 | 2026-04-01 | The University of Texas Health Science Center at San Antonio |
| NCT07457437 | Function and Lean Mass Preservation With Resistance Exercise During a GLP-1RA Treatment | Not applicable | Recruiting | 60 | 2026-04-01 | University of Exeter |
| NCT07504172 | Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity | N/A | Completed | 915 | 2026-04-01 | Radboud University Medical Center |
| NCT07521631 | Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Phase 2 | Recruiting | 372 | 2026-03-31 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| NCT07589322 | Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | Not applicable | Recruiting | 120 | 2026-03-31 | Tri-Service General Hospital (TSGH) |
| NCT07443956 | Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis | Not applicable | Recruiting | 45 | 2026-03-09 | NHS Greater Glasgow and Clyde |
| NCT07463846 | A Study to Evaluate ALN-2232 in Participants With Obesity | Phase 1 / Phase 2 | Recruiting | 156 | 2026-03-02 | Alnylam Pharmaceuticals |
| NCT07483801 | DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Phase 4 | Not yet recruiting | 112 | 2026-03 | Cambridge University Hospitals NHS Foundation Trust |
| NCT07492563 | Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay | N/A | Not yet recruiting | 300 | 2026-03 | LABORATORIOS INDUFAR |
| NCT07220473 | Tirzepatide to Slow Biological Aging | Phase 2 | Recruiting | 90 | 2026-02-27 | The University of Texas Medical Branch, Galveston |
| NCT07438444 | A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity | Phase 4 | Active not recruiting | 344 | 2026-02-27 | Eli Lilly and Company |
| NCT07685834 | Evaluation of Facial and Neck Skin Laxity With SofWave Treatment in Adults Initiating Tirzepatide for Weight Loss | Not applicable | Active not recruiting | 30 | 2026-02-27 | Sofwave Medical LTD |
| NCT07095517 | Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | Phase 1 | Recruiting | 20 | 2026-02-24 | Massachusetts General Hospital |
| NCT07619508 | Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes. | N/A | Completed | 100000 | 2026-02-10 | Brigham and Women's Hospital |
| NCT07481747 | Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Phase 3 | Recruiting | 2539 | 2026-02-02 | Hudson Biotech |
| NCT07176663 | Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure | Not applicable | Not yet recruiting | 15 | 2026-02-01 | Shahid Beheshti University of Medical Sciences |
| NCT06651177 | Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Phase 2 | Recruiting | 310 | 2026-01-29 | T. John Winhusen, PhD |
| NCT07417618 | INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) | N/A | Completed | 60000 | 2026-01-27 | Brigham and Women's Hospital |
| NCT07398222 | Gastric Content in Fasting Volunteers and in Tirzepatide Users: an Observational and Cross-sectional Study | N/A | Recruiting | 30 | 2026-01-26 | Hospital Israelita Albert Einstein |
| NCT07354880 | Effect of Tirzepatide on Cardiovascular and Metabolic Parameters in Obese Adult Patients With Congenital Heart Disease | Phase 4 | Not yet recruiting | 30 | 2026-01-20 | University Medical Centre Ljubljana |
| NCT07292519 | Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB) | Phase 2 | Not yet recruiting | 46 | 2026-01-15 | South West Sydney Local Health District |
| NCT07299084 | A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus | Phase 1 | Active not recruiting | 40 | 2026-01-14 | Eli Lilly and Company |
| NCT07423247 | Tirzepatide (Spartina) in Obese Kidney Transplant Recipients | Phase 4 | Recruiting | 30 | 2026-01-01 | Shahid Beheshti University of Medical Sciences |
| NCT07640139 | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | N/A | Enrolling by invitation | 125000 | 2026-01-01 | Indiana University |
| NCT07364175 | A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults | Not applicable | Recruiting | 60 | 2026-01 | Cambridge University Hospitals NHS Foundation Trust |
| NCT07373834 | Tirzepatide and Muscle Outcomes in Obesity | Not applicable | Recruiting | 30 | 2026-01 | University Medical Centre Ljubljana |
| NCT07319975 | Effect of Semaglutide and Tirzepatide Combined With Exercise in Obesity | Not applicable | Not yet recruiting | 48 | 2025-12-29 | Istanbul Galata University |
| NCT07326111 | A Clincial Study Testing Tirzepatide on Reproductive Function and Metabolic Health in Women With PCOS Who Are Overweight or Obese | Phase 4 | Recruiting | 198 | 2025-12-09 | University of Bonn |
| NCT07247084 | A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) | Phase 4 | Recruiting | 3000 | 2025-11-24 | Eli Lilly and Company |
| NCT07834398 | Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes | Phase 3 | Completed | 150 | 2025-11-14 | Zagazig University |
| NCT06935838 | Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV | Phase 2 | Completed | 12 | 2025-11-12 | University of Hawaii |
| NCT07262762 | Spartina® (Tirzepatide) Effectiveness and Safety Evaluation | N/A | Completed | 175 | 2025-11-11 | Cinnagen |
| NCT05933499 | Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity | Phase 2 | Recruiting | 63 | 2025-11-05 | Massachusetts General Hospital |
| NCT07202247 | Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Phase 2 | Recruiting | 60 | 2025-11-05 | City of Hope Medical Center |
| NCT07245771 | Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity | Phase 1 / Phase 2 | Recruiting | 104 | 2025-11-04 | Ikaria Bioscience Pty Ltd |
| NCT07128082 | The Long COVID Treatment Trial | Phase 2 | Active not recruiting | 1000 | 2025-10-30 | Scripps Translational Science Institute |
| NCT07820111 | Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial | Phase 3 | Completed | 159 | 2025-10-18 | Zagazig University |
| NCT07165028 | A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Recruiting | 4500 | 2025-10-15 | Eli Lilly and Company |
| NCT07154719 | GLP-1R Actions on Muscle and the Skeleton | Phase 4 | Recruiting | 50 | 2025-10-09 | Pennington Biomedical Research Center |
| NCT06994338 | Tirzepatide for Alcohol Use Disorder | Phase 2 | Recruiting | 42 | 2025-10-06 | University of Southern California |
| NCT06801015 | Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Phase 4 | Active not recruiting | 30 | 2025-10-01 | Mayo Clinic |
| NCT07203677 | Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT) | N/A | Completed | 49065 | 2025-09-19 | Brigham and Women's Hospital |
| NCT06847399 | Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder | Phase 2 | Recruiting | 105 | 2025-09-17 | Johns Hopkins University |
| NCT06727331 | Study of Tirzepatide for Recovery and Alcohol Use Management | Phase 2 | Recruiting | 20 | 2025-09-15 | Brigham and Women's Hospital |
| NCT07091734 | Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024 | Phase 2 | Recruiting | 32 | 2025-09-08 | University of Michigan |
| NCT07115069 | Comparison of Body Composition Changes With Weight Loss Interventions | N/A | Active not recruiting | 60 | 2025-08-09 | Vanderbilt University Medical Center |
| NCT06885736 | LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy | Not applicable | Recruiting | 232 | 2025-08-07 | Dasman Diabetes Institute |
| NCT07096908 | Tirzepatide Use in People With Obesity and Type 1 Diabetes | Phase 4 | Recruiting | 60 | 2025-07-31 | Dasman Diabetes Institute |
| NCT06861439 | GLP-1s to Enhance Lasting Optimal Weight | Phase 4 | Active not recruiting | 40 | 2025-07-07 | Wake Forest University Health Sciences |
| NCT06759701 | Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study | Early phase 1 | Recruiting | 30 | 2025-07-02 | M.D. Anderson Cancer Center |
| NCT06934642 | Effect of Tirzepatide on Markers of MASLD in Patients With Obesity | Early phase 1 | Recruiting | 8 | 2025-06-30 | University of New Mexico |
| NCT06937086 | Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study | Phase 3 | Recruiting | 350 | 2025-06-26 | Eli Lilly and Company |
| NCT06937099 | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | Phase 3 | Recruiting | 290 | 2025-06-26 | Eli Lilly and Company |
| NCT07000955 | Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Phase 1 / Phase 2 | Active not recruiting | 98 | 2025-06-17 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07293325 | Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity | Not applicable | Recruiting | 66 | 2025-06-02 | Second Affiliated Hospital, Zhejiang University, School of Medicine |
| NCT06901349 | A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes | Phase 2 | Withdrawn | 0 | 2025-05-23 | Eli Lilly and Company |
| NCT07094568 | Tirzepatide vs Liraglutide in Bone | N/A | Recruiting | 72 | 2025-05-23 | National and Kapodistrian University of Athens |
| NCT06976853 | Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease | Phase 2 | Recruiting | 60 | 2025-05-13 | Washington University School of Medicine |
| NCT06962280 | A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Active not recruiting | 465 | 2025-05-12 | Eli Lilly and Company |
| NCT06939088 | Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder | Phase 2 | Recruiting | 108 | 2025-05-05 | Anders Fink-Jensen, MD, DMSci |
| NCT06965413 | A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Phase 2 | Active not recruiting | 285 | 2025-05-05 | Hoffmann-La Roche |
| NCT06901245 | Tirzepatide in PWS, HO and GNSO | Phase 4 | Recruiting | 36 | 2025-05-01 | Grace Kim |
| NCT07057310 | Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women | Phase 4 | Enrolling by invitation | 30 | 2025-05-01 | Mayo Clinic |
| NCT06914895 | A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Active not recruiting | 905 | 2025-04-25 | Eli Lilly and Company |
| NCT06911203 | A Study of BGM0504 in Participants With Obesity | Phase 2 | Completed | 96 | 2025-04-09 | BrightGene Bio-Medical Technology Co., Ltd. |
| NCT06916065 | A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity | Phase 1 | Completed | 188 | 2025-04-09 | Eli Lilly and Company |
| NCT06802081 | TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation | Phase 2 | Recruiting | 100 | 2025-04-08 | The Cleveland Clinic |
| NCT06897475 | A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Recruiting | 200 | 2025-03-28 | Eli Lilly and Company |
| NCT06721507 | 2024 Tirzepatide-Bariatric Surgery | Phase 4 | Recruiting | 50 | 2025-03-27 | Marlene Starr |
| NCT06890611 | A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants | Phase 1 | Completed | 125 | 2025-03-25 | Eli Lilly and Company |
| NCT06857942 | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) | Phase 4 | Recruiting | 200 | 2025-03-19 | Eli Lilly and Company |
| NCT06893211 | Effect of Tirzepatide on Brown Adipose Tissue in Obesity | Phase 2 | Completed | 34 | 2025-03-18 | University Medical Centre Ljubljana |
| NCT06734273 | Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss | Early phase 1 | Active not recruiting | 42 | 2025-03-10 | Nicholas Skertich |
| NCT06582875 | Glucagon-Like Peptide-1 Receptor Agonist in ADPKD | Phase 2 | Recruiting | 126 | 2025-03-06 | University of Colorado, Denver |
| NCT06864026 | A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Active not recruiting | 200 | 2025-03-06 | Eli Lilly and Company |
| NCT06774079 | Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients | Phase 4 | Active not recruiting | 24 | 2025-03-05 | University of Miami |
| NCT06854614 | Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial) | Phase 4 | Active not recruiting | 150 | 2025-03-01 | The Cleveland Clinic |
| NCT06737042 | Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants | Phase 2 | Completed | 326 | 2025-02-24 | Gan and Lee Pharmaceuticals, USA |
| NCT06630585 | GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes | Phase 3 | Recruiting | 42 | 2025-02-14 | University of Bern |
| NCT06745128 | Tirzepatide for Obesity and Meth Use Disorder | Phase 2 | Completed | 35 | 2025-02-03 | University of Texas Southwestern Medical Center |
| NCT07382180 | Real-World Tirzepatide Therapy in Post-Bariatric Weight Regain and Preoperative Obesity Patients | N/A | Completed | 254 | 2025-02-01 | Azienda Sanitaria Locale Napoli 2 Nord |
| NCT06803888 | Bariatric Surgery vs. Semaglutide vs. Tirzepatide | Phase 4 | Active not recruiting | 140 | 2025-01-29 | Ali Aminian |
| NCT06914141 | Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction | N/A | Completed | 28118 | 2025-01-14 | Brigham and Women's Hospital |
| NCT06914154 | Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data | N/A | Completed | 11265 | 2025-01-14 | Brigham and Women's Hospital |
| NCT06657209 | Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide | Phase 4 | Recruiting | 104 | 2025-01-13 | Stanford University |
| NCT07740291 | Tirzepatide Impact Assessment Study | Not applicable | Recruiting | 27 | 2025-01-02 | Texas Tech University |
| NCT06918405 | Efficacy and Safety of Tirzepatide for Weight Management | Phase 3 | Active not recruiting | 440 | 2025-01-01 | Chittagong Medical College |
| NCT06980623 | Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction | N/A | Active not recruiting | 26000 | 2025-01-01 | Brigham and Women's Hospital |
| NCT07638592 | Tirzepatide-Based Prehabilitation Before Elective Ventral and Incisional Hernia Repair in Patients With Obesity | N/A | Completed | 91 | 2025-01-01 | Azienda Sanitaria Locale Napoli 2 Nord |
| NCT06751589 | A Study of a Weight Loss Intervention in People With Endometrial Cancer | Early phase 1 | Active not recruiting | 4 | 2024-12-19 | Memorial Sloan Kettering Cancer Center |
| NCT07303556 | Improving Cardiovascular Disease Diagnosis and Treatment in Kazakhstan Using Metabolic Correction With GLP-1 Drugs | Not applicable | Active not recruiting | 120 | 2024-12-18 | Nazarbayev University |
| NCT06648031 | Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Phase 1 | Completed | 148 | 2024-12-04 | Lexaria Bioscience Corp. |
| NCT06700538 | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Phase 1 / Phase 2 | Active not recruiting | 190 | 2024-12-04 | Arrowhead Pharmaceuticals |
| NCT06517212 | Tirzepatide Weight Loss for MRD+ Early Breast Cancer | Phase 2 | Recruiting | 48 | 2024-11-26 | Baylor Research Institute |
| NCT06191848 | Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA) | Phase 4 | Active not recruiting | 352 | 2024-11-19 | University of Melbourne |
| NCT06246799 | Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes | Phase 3 | Recruiting | 256 | 2024-11-07 | The University of Texas Health Science Center at San Antonio |
| NCT06534411 | A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both | Phase 3 | Completed | 1023 | 2024-11-05 | Novo Nordisk A/S |
| NCT06662383 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Phase 3 | Active not recruiting | 800 | 2024-11-01 | Eli Lilly and Company |
| NCT06779929 | Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes | N/A | Completed | 70000 | 2024-11-01 | Brigham and Women's Hospital |
| NCT06162715 | GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial | Phase 2 / Phase 3 | Active not recruiting | 30 | 2024-10-30 | Vanderbilt University Medical Center |
| NCT06518837 | Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Phase 2 | Recruiting | 40 | 2024-10-30 | Rutgers, The State University of New Jersey |
| NCT06643728 | A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight | Phase 2 | Active not recruiting | 252 | 2024-10-21 | Eli Lilly and Company |
| NCT06575738 | Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents | Phase 1 | Recruiting | 40 | 2024-10-11 | University of Colorado, Denver |
| NCT06635057 | A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan | Phase 4 | Completed | 166 | 2024-10-11 | Eli Lilly and Company |
| NCT06606821 | The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease | Phase 4 | Recruiting | 124 | 2024-10-01 | Tina Vilsbøll |
| NCT07088718 | Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data | N/A | Completed | 44671 | 2024-10-01 | Brigham and Women's Hospital |
| NCT07096063 | Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk | N/A | Completed | 887132 | 2024-10-01 | Brigham and Women's Hospital |
| NCT06588283 | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight | Phase 3 | Completed | 281 | 2024-09-30 | Eli Lilly and Company |
| NCT06640972 | Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists | Phase 2 | Completed | 68 | 2024-09-27 | Response Pharmaceuticals |
| NCT06588296 | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight | Phase 3 | Completed | 279 | 2024-09-24 | Eli Lilly and Company |
| NCT06603571 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Phase 2 | Completed | 367 | 2024-09-20 | Eli Lilly and Company |
| NCT06605703 | A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial) | Phase 4 | Completed | 226 | 2024-09-18 | WW International Inc |
| NCT06485089 | Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers | N/A | Completed | 25 | 2024-09-14 | University of Kansas Medical Center |
| NCT06484114 | Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide | Not applicable | Active not recruiting | 315 | 2024-09-01 | Fractyl Health Inc. |
| NCT06565611 | A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity | Phase 2 | Active not recruiting | 108 | 2024-08-05 | Palatin Technologies, Inc |
| NCT06533527 | Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy | Phase 4 | Completed | 69 | 2024-07-31 | The Cleveland Clinic |
| NCT06515418 | Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over | Phase 2 | Terminated | 204 | 2024-06-27 | BioAge Labs, Inc. |
| NCT06439277 | A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2) | Phase 3 | Recruiting | 300 | 2024-06-03 | Eli Lilly and Company |
| NCT06445075 | Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese | Phase 2 | Completed | 102 | 2024-05-21 | Scholar Rock, Inc. |
| NCT06400615 | Study That Tests AD109 in Patients Taking GLP-1 Drugs | Phase 2 | Completed | 40 | 2024-05-20 | Apnimed |
| NCT06373146 | A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity | Phase 2 | Completed | 392 | 2024-04-24 | Eli Lilly and Company |
| NCT06297616 | A Study of LY3841136 in Japanese Participants With Obesity or Overweight | Phase 1 | Completed | 128 | 2024-04-15 | Eli Lilly and Company |
Showing 200 of 270 studies, most recent start first.
Method and limitations
- Data source: ClinicalTrials.gov API v2, intervention search.
- Query used:
Tirzepatide OR Mounjaro OR Zepbound OR LY3298176 - Retrieved: November 2, 2026. Refreshed weekly; changes are reviewed before publication.
- Studies registered only under other names, sponsor codes, or in other registries may be missing.
- A match on name does not mean the study tested this peptide alone; some studies include it as a comparator or combination.
- Status values are reported by sponsors and may be out of date.